文献速递前列腺增生与排尿功能障碍

iTind临时植入镍钛装置治疗良性前列腺增生相关下尿路症状:多中心随机对照试验

The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial.
PubMed 文献 · Urology · 2020-12-26

这项多中心随机对照试验将175名50岁以上下尿路症状继发于良性前列腺增生的男性按2:1随机分配至iTind组(118例)或假手术组(57例),iTind装置临时放置5-7天。3个月时iTind组78.6%患者IPSS降低≥3分,对照组为60%;不良事件多为轻度和一过性,无新发射精或勃起功能障碍。

要点

  • 3个月时iTind组78.6%患者IPSS降低≥3分,对照组为60%。
  • 不良事件多为Clavien-Dindo I或II级,iTind组38.1%,对照组17.5%。

核心结论

  • 第二代iTind治疗可快速且持续改善良性前列腺增生继发的下尿路症状,并保留性功能。

研究设计与样本

  • 多中心、随机、对照试验,男性50岁及以上,按2:1随机分配至iTind组(118例)或假手术组(57例)。
  • iTind装置自膨胀临时放置5-7天;假手术组插入并移除18F Foley导尿管。
  • 基线、术后1.5、3、12个月评估IPSS、峰值尿流率、残余尿、生活质量及国际勃起功能指数;3个月揭盲。

主要发现

  • 3个月时iTind组78.6%患者IPSS降低≥3分,对照组为60%。
  • 不良事件多为轻度和一过性,大多数为Clavien-Dindo I或II级,iTind组发生率为38.1%,对照组为17.5%。
  • 无新发射精或勃起功能障碍。

关键数值与推荐

  • iTind组3个月IPSS降低≥3分应答率为78.6%,对照组为60%。
  • 不良事件Clavien-Dindo I或II级占比:iTind组38.1%,对照组17.5%。

临床怎么用

  • 对于寻求微创治疗且希望保留性功能的良性前列腺增生相关下尿路症状患者,iTind可作为临时植入选项。
  • 治疗期间需放置5-7天,不良事件多为轻度一过性,需告知患者可能的Clavien-Dindo I-II级事件。
  • 12个月随访显示症状和尿流率持续改善,但需注意研究揭盲时间为3个月。

局限性

  • 3个月即揭盲,12个月结果可能受开放标签影响。
  • 样本量175例,对照组57例,长期(>12个月)数据未报告。
  • 未报告残余尿、国际勃起功能指数等具体数值变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To report the results of a multicenter, randomized, controlled trial with a temporarily implanted nitinol device (iTind; Medi-Tate Ltd, Hadera, Israel) compared to sham for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. MATERIALS AND METHODS: Men 50 years or older were randomized 2:1 between iTind and sham procedure arms. A self-expanding, temporary nitinol device was placed for 5-7 days and an 18F Foley catheter was inserted and removed for the iTind and sham group, respectively. Patients were assessed at baseline, 1.5, 3, and 12 months postoperatively using the IPSS, peak urinary flow rate, residual urine, quality of life, and the International Index of Erectile Function. Unblinding occurred at 3 months. RESULTS: A total of 175 men (mean age 61.1 ± 6.5) participated (118 iTind vs 57 sham). A total of 78.6% of patients in the iTind arm showed a reduction of ≥3 points in IPSS, vs 60% of patients in the control arm at 3 months. At 12 months, the iTind group reported a 9.25 decrease in IPSS (P< .0001), a 3.52ml/s increase in peak urinary flow rate (P < .0001) and a 1.9-point reduction in quality of life (P < .0001). Adverse events were typically mild and transient, most Clavien-Dindo grade I or II, in 38.1% of patients in the iTind arm and 17.5% in the control arm. No de novo ejaculatory or erectile dysfunction occurred. CONCLUSION: Treatment with the second-generation iTind provided rapid and sustained improvement in lower urinary tract symptoms for the study period while preserving sexual function.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Chughtai B, Elterman D, Shore N, et al. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Urology. 2020. PMID: 33373708. doi:10.1016/j.urology.2020.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。